Compare NCMI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCMI | ARMP |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.6M | 199.7M |
| IPO Year | 2006 | 1996 |
| Metric | NCMI | ARMP |
|---|---|---|
| Price | $2.46 | $5.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $5.63 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.6M | 94.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 52.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.20 | N/A |
| Revenue Next Year | $6.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.16 | $2.83 |
| 52 Week High | $5.03 | $14.98 |
| Indicator | NCMI | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 57.69 |
| Support Level | $2.16 | $5.66 |
| Resistance Level | $3.74 | $6.60 |
| Average True Range (ATR) | 0.12 | 0.48 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 18.39 | 91.98 |
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.